Synthetic polypeptides(s) useful for vaccination against Streptococcus pyogenes

Patent Report Genetically reassorted virus for vaccine production against horse influenza Wellcome Eur 113-665:18 July 1984 A genetically reassorted virus comprising R N A derived from a horse influenza virus a n d coding for at least one surface antigen, a n d an R N A segment derived from h u m a n influenza virus A/ Puerto Rico/8/34 a n d coding for matrix protein, is described. T h e horse influenza virus is A / E q l / N e w m a r k e t / 7 7 or A/Eq2/ Brentwood/79, and the R N A derived from it codes for a h a e m a g g l u t i n i n or neuroaminidase. The parent viruses are cultured in hen eggs at 37°C, for 24-48 h. Viruses having surface antigens derived from only the horse virus are then selected, a n d from these are selected those which will grow in cell culture. Viruses of this type are useful for preparing vaccine against horse influenza. Unlike the parent horse influenza virus, they can be grown in cell culture (e.g. Vero cells) as well as in fertile h e n eggs. 007-85

Babesiosis vaccine prepared from soluble parasitic antigen factors isolated from disintegration of babesia infected erythrocytes and tested in cattle Goodger, B. V. US 4A57,915:3 July 1984 The invention relates to the preparation of a babesiosis vaccine derived from non-living antigenic material. Infected erythrocytes are used a n d the vaccine prepared was tested in cattle. In an example, infected erythrocytes concentrated from infected blood by differential lysis were sonicated to give a material termed infected erythrocytic antigen (lEA). This was stored frozen a n d thawed a n d fractionated prior to use. A crude soluble extract (CSE), the s u p e r n a t a n t fluid o b t a i n e d by centrifugation of lEA, was fractionated to remove h a e m o g l o b i n with C M Sephadex a n d to precipitate the fibrinogen-associated antigens (FAA) of Babesia bovis. The m e t h o d involved with precipitation of fibrinogen at 37°C by mixing CSE with either a solution c o n t a i n i n g CaCI 2 and t h r o m b i n or with aq. p r o t a m i n e sulphate. The insoluble precipitate was discarded a n d the residual s u p e r n a t a n t fluid after FAA precipitation was designated the soluble parasitic extract (SPE). This was used to prepare a vaccine for cattle inoculation. 008-85

Vaccine against Aujeszky's disease obtained by extraction of glycoprotein gX from pseudorabies virus infected African green monkey kidney cell culture Upjohn Eur 115-442; 8 August 1984 A vaccine for protecting an a n i m a l against pseudorabies virus (PRV) consists of a sulphate glycoprotein (gX) of 95000 MW. A cell culture of African green monkey kidney cells in Dulbecco's modified Eagle's m e d i u m s u p p l e m e n t e d with penicillin, streptomycin, HEPES, glutamine a n d fetal bovine serum is infected with PRV o b t a i n e d from pigs. After 10-12 h, the m e d i u m is removed and the r e m a i n i n g cells washed with Dulbecco's modified Eagle's m e d i u m without serum supplement. The cells are incubated for a further 4 h at 37°C, a n d the resulting s u p e r n a t a n t is collected a n d centrifuged. The s u p e r n a t a n t is treated with perchloric acid to I% concentration. After incubating for l0 rain on ice, further material is removed by precipitation, a n d the s u p e r n a t a n t is neutralized with Tris base. Glycoprotein gX and other proteins are precipitated by addition of acetone. The vaccine is useful for protecting a n i m a l s against PRV infections (also known as Aujeszky's disease), m a d itch and b u l b a r paralysis. 009-85

B-oligomer containing pertussis vaccine and preparation thereof Bordetella pertussis Kaken Japan, u n e x a m i n e d 9110-626; 26 June 1984 A pertussis vaccine contains, as the active ingredient, the Boligomer ofBordetella pertussis. B. pertussis phase I or phase II cells are ct, ltured, a n d the s u p e r n a t a n t obtained from the

74

Vaccine, Vol. 3, March 1985

cultured solution is treated with hydroxyapatite to the insulin activator protein ( l A P or N-lAP) crude fraction. Urea is added to the crude fraction to a concentration of 3-6 M and then incubated for 2-48 h, treated with haptoglobin-Sepharose and purified. The vaccine is superior to conventional HA-vaccine in that it is free from side-effects, does not contain endotoxin, a n d has a higher prophylactic effect. 010-85

Synthetic polypeptides(s) useful for vaccination against Streptococcus pyogenes Univ. Tennessee US 4,454,-121; 12 J u n e 1984 The polypeptides having the a m i n o acid sequence of Asn-PhcSer-Thr-Ala-Asp-Ser-Ala- Lys-Ile- Lys-Thr- Leu- Glu-Ala-GluLys-(Ala) 2-Leu-(AI a)z-Arg- Lys-Ala-Asp- Leu-G lu- Lys-AI a- LeuGlu-Gly-Ala-Met (1) a n d (Ala):-Leu-(Ala)z-Arg-Lys-Ala-As pLeu-Glu-Lys-(Gly) 3 (II) are new. Peptide fragments having the a m i n o acid sequences of Lys-Ala-Asp-Leu-Glu-Lys-Ala-LeuGlu-Gly-Ala-Met (Ill) and Asn-Phe-Ser-Thr-Ala-Asp-Ser-AlaLys-Ile-Lys-Thr-Leu-Glu-Ala-Glu-Lys-(Ala)2-Leu (Ala)z-Arg (VI) are also new. A synthetic antigen for eliciting type-specific opsonic antibodies or cellular i m m u n i t y toStreptococcuspyogenes comprises a polyvalent linkable carrier covalently linked to(l) or (II). The synthetic peptides correspond to antigenic d e t e r m i n a n t s of the M protein ofStr, pyogenes a n d can be used for vaccination, especially when c o m b i n e d in the specific antigens. The small peptide fragments permit the development of safe a n d effective vaccines against streptococcal infections initiating r h e u m a t i c fever and rheumatic heart disease. 011-85

Vaccinal complex containing a specific antigen and vaccine containing it, bacterial rRNA coupling with specific antigen of bacterial serotype e.g. Klebsiella pneumoniae, Escherichia coil Salmonella typhimurium etc. Pierre-Fabre US 4,460,575" 17 July 1984 Vaccine complexes comprise bacterial rRNA (fragments) on which is coupled 1-5 wt% of a specific antigen bacterial serotype. The rRNA and the specific antigen may originate from the same different bacteria. The rRNA is preferably extracted from the ribosomes of Str~7~tococcus pneumoniae. St~Tmcoccus IO'ogene~,

Staphylococcus aureus, Klebsiella pneumoniae. Serratia marcescenx k,~cherichia coil Salmonella typhimurium, (oo,nebacterium or Mycobacterium. Bacterial rRNA fragments preferably have MW,~ of 30 000 to 200 000. A m o n g preferred specific antigens are capsular polysaccharides of Klebz pneumoniae. Strept. pneumoniae, Hemophilus influenzae a n d m e m b r a n e lipopolysaccharides of Gram-negative bacteria, such as Klcbx

pneumonia~; S marcescen.~ F,. col~ Neisseria meningitidix Sahnonella typhimurium: specific m e m b r a n e proteins ofk.] colt S marce~cen~; Salm. o'phimurium a n d Strept. t~w~gene~; and teichoic acid and lipoteichoic acids ofStrept., Staph., andLactobacil spp. 012-85 Expression of Plasmodium falciparum polypeptides from cDNA for use in immunization against malarial infection Hall-Inst. Med Res World 8402-917; 2 August 1984 D N A molecules comprising artificially constructed polynucleotide sequence substantially corresponding to all or to a portion of Plasmodiumfalciparum m R N A or genomic D N A are described. The r e c o m b i n a n t D N A molecule is linked to an expression control sequence in a vector which is inserted into a host cell, e.g. t:~cherichia colt which produces a synthetic peptide or polypeptide with the antigenicity of all or part of a P falciparum antigen. The polypeptide stimulates i m m u n e responses against P falciparum antigens in a mamrnal. A virus or microorganism with the D N A molecule inserted may be used in this capacity instead of the polypeptide. In an example, P .fidciparum rnRNA is used to construct e D N A clones in lambda-gtl0. Phage l a m b d a - A m p 3 was constructed from pBIL'~22 and l a m b d a - g t l l D N A and l a m b d a - g t l 0 e D N A was inserted into this phage. The library constructed was screened with P fidciparum antibodies. 013-85